ChromaDex Corporation Reports Third Quarter 2024 Financial Results

In This Article:

Total net sales of $25.6 million, up $6.1 million or 31% year-over-year, gross margin of 63.5% and record net income and adjusted EBITDA of $1.9 million and $2.9 million, respectively, for the three months ended September 30, 2024

LOS ANGELES, October 31, 2024--(BUSINESS WIRE)--ChromaDex Corp. (NASDAQ:CDXC) today announced financial results for the third quarter of 2024.

Third Quarter 2024 Financial and Recent Operational Highlights

  • Total net sales were $25.6 million, with $18.1 million from Tru Niagen®, up 31%, and 4%, respectively, from the prior year quarter.

  • Total Niagen® ingredient sales, including food-grade and pharmaceutical-grade, reached $6.7 million, up 368% YoY.

  • Delivered strong gross margin of 63.5%, up 210 basis points from the prior year quarter.

  • Sales and marketing expense as a percentage of net sales was 27.5%, an improvement of 350 basis points, compared to 31.0% from the prior year quarter.

  • Achieved net income of $1.9 million or $0.02 earnings per share, an improvement of $2.8 million and $0.03 per share from the prior year quarter.

  • Reached record Adjusted EBITDA, a non-GAAP measure, of $2.9 million, up $2.4 million from the prior year quarter.

  • In September 2024, ChromaDex expanded the availability of Niagen+, a product line containing pharmaceutical-grade Niagen®, to an additional 14 leading wellness clinics. These Niagen+ products, including Niagen® IV and Niagen® Injections, are compounded and distributed by U.S. FDA-registered 503B outsourcing facilities and are available exclusively by prescription at participating wellness clinics. As of October 31, 2024, ChromaDex has expanded Niagen+ availability to over 100 wellness clinics, with further significant expansion expected in the coming weeks.

  • In September 2024, ChromaDex marked its 25th anniversary. Over the past 25 years, ChromaDex has built a reputation as the gold standard for scientific rigor and quality. With over 275 research agreements worldwide, more than 175 peer-reviewed publications, and over 30 human clinical studies on Niagen®, the ChromaDex External Research Program (CERP™) has played a pivotal role in advancing the scientific understanding of NAD+ and its role in age-related health conditions.

  • ChromaDex has initiated discussions with the FDA and is working to schedule meetings as part of the Company’s efforts to pursue an Investigational New Drug (IND) application for the use of nicotinamide riboside (NR) in the treatment of Ataxia Telangiectasia (AT). AT is a rare, progressive disease that typically presents in early childhood and affects the function of the nervous system, the immune system, and several other body systems.